■ 氏名
小島 研介 (コジマ ケンスケ)
KOJIMA Kensuke

■ 所属部局/職名
Research and Education Faculty, Medical Sciences Cluster, Clinical Medicine Unit/Professor
教育研究部 医療学系 臨床医学部門/教授
Adjunct Associate Professor, Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

■ 学部・学科・コース等
Medical School, Medical Course
医学部 医学科 血液内科学

■ 連絡先
住 所
電 話
F A X
E-Mail
U R L

■ 出身大学院・研究科等
岡山大学 博士(医学研究科 内科学(二)) 1995 (修了)

■ 出身学校・専攻等
岡山大学 (医学部 ) 1991 (卒業)

■ 取得学位
医学博士 (課程) 岡山大学 血液内科学

■ 研究職歴
米国テキサス州立大学MDアンダーソンがんセンター准教授(2009-2013)
米国テキサス州立大学MDアンダーソンがんセンター客員准教授(2013-)

■ 委員歴・役員歴
日本血液学会代議員
日本がん分子標的治療学会評議員

■ 受賞学術賞
かなえ医薬振興財団 研究留学助成 (2003年)
持田記念医学薬学振興財団 研究留学助成 (2003年)
上原記念生命科学財団 研究留学助成 (2004年)
かなえ医薬振興財団 研究助成 (2007年)
ノバルティス科学振興財団 研究奨励 (2008年)
公益信託日本白血病研究基金 一般研究賞 (2008年)
財団法人安田記念医学財団 海外研究助成 (2008年)
公益信託日本白血病研究基金 一般研究賞 (2011年)
大阪癌研究会一般学術研究助成金 (2013年)
高松宮妃癌研究基金 研究助成 (2014年)
日本対がん協会リレー・フォー・ライフ・ジャパン「プロジェクト未来」研究助成 (2016年)
財団法人安田記念医学財団 癌研究助成 (2016年)
公益財団法人がん研究振興財団がん研究助成金 (2017年)
公益信託日本白血病研究基金 一般研究賞 (2018年)

■ 所属学会
日本内科学会
 ( )
日本血液学会
 ( )
米国血液学会
 ( )
米国がん研究学会
 ( )
日本がん分子標的治療学会
 ( )
日本癌学会会員
 ( )
日本リンパ網内系学会
 ( )
日本造血細胞移植学会
 ( )
日本感染症学会
 ( )
日本遺伝カウンセリング学会
 ( )

■ 専門分野
血液内科学、分子血液腫瘍学、分子標的治療学

■ 主な研究テーマ・活動
造血器腫瘍におけるp53シグナル制御と分子標的治療

■ 研究についてのPR
血液疾患の基礎・臨床研究によって、原因、病態の究明から治療法の改良・開発まで、一連のシークエンスとして血液疾患を理解したいと考えています。前臨床では、現在の医学レベルでは治癒が容易でない造血器腫瘍を治癒せしめるような、新たな分子標的治療戦略の確立を目指しています。具体的には、造血器腫瘍で機能的に破綻しているp53経路を主たる標的として、これの再活性化あるいはバイパス治療戦略を提唱してきました。また、臨床研究とともに、臨床医のみがなしうる症例報告は、臨床教室においては非常に重要な価値をもつものと考えております。

■ 社会人・生徒を対象として可能な講演・授業(例えば講演題目)
血液内科学、造血器腫瘍の診療

■ 研究業績(論文・解説)
1. Omoto E*, Deguchi S, Takaba S, Kojima K, Yano T, Katayama Y, Sunami K, Takeuchi M, Kimura F, Harada M, Kimura I. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia. 1996; 10:609-614.
  () /, ()

2. Katayama Y*, Kojima K, Yoshino T, Matsuo Y, Isokawa M, Yano T, Oka H, Yamaguchi M, Deguchi S, Tsuchiyama J, Hayashi K, Teshima T, Shinagawa K, Ishimaru F, Omoto E, Harada M. Common clonal origin of lymphocytes and plasma cells in splenic lymphoma with villous lymphocytes. Br J Haematol. 1997; 97:626-634.
  () /, ()

3. Matsuo Y*, Macleod RAF, Kojima K, Kuwahara K, Sakata A, Drexler HG, Nishizaki C, Fukuda S, Inoue Y, Sezaki T, Sakaguchi N, Orita K. A novel ALL-L3 cell line, BALM-16, lacking expression of immunoglobulin chains derived from a patient with hypercalcemia. Leukemia. 1997; 11:2168-2174.
  () /, ()

4. Kojima K*, Kobayashi H, Imoto S, Nakagawa T, Matsui T, Kawachi Y, Oda K, Yano T, Kobayashi H, Noguchi M, Hara M, Oshimi K. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia. Int J Hematol. 1998; 68:291-296.
  () /, ()

5. Hara M*, Shinagawa K, Omoto E, Sunami K, Deguchi S, Narumi H, Kojima K, Azuma T, Takamatsu H, Nakao S, Harada M. Graft rejection and recovery of host-derived hematopoiesis after allogeneic bone marrow transplantation: relation to conditioning with high dose etoposide and total body irradiation. Int J Hematol. 1998; 68:95-100.
  () /, ()

6. Kojima K*, Sawada T, Ikezoe T, Matsuo Y, Kobayashi H, Yano T, Sugimoto T, Imoto S, Nakagawa T, Matsui T, Yasukawa M, Hara M, Taguchi H. Defective human T-lymphotropic virus type I provirus in T-cell prolymphocytic leukaemia. Br J Haematol. 1999; 105:376-381.
  () /, ()

7. Kojima K*, Yasukawa M, Miyakuni T, Harashima A, Matsuo Y, Yano T, Sezaki T, Kobayashi H, Hara M. Serum levels of parathyroid hormone related protein are not elevated in patients with T-cell prolymphocytic leukemia. Ann Hematol. 1999; 78:415-417.
  () /, ()

8. Katayama Y*, Mahmut N, Takimoto H, Maeda Y, Yano T, Kojima K, Azuma T, Hara M, Imajyo K, Takahashi S, Kai T, Ohno Y, Miyamoto T, Nagafuji K, Matsue K, Takenaka K, Teshima T, Shinagawa K, Ishimaru F, Omoto E, Harada M. Hematopoietic progenitor cells from allogeneic bone marrow transplant donors circulate in the very early post-transplant period. Bone Marrow Transplant. 1999; 23:659-665.
  () /, ()

9. Maeda Y*, Teshima T, Yamada M, Shinagawa K, Nakao S, Ohno Y, Kojima K, Hara M, Nagafuji K, Hayashi S, Fukuda S, Sawada H, Matsue K, Takenaka K, Ishimaru F, Ikeda K, Niiya K, Harada M. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Br J Haematol. 1999; 105:295-302.
  () /, ()

10. Nakayama H, Ishimaru F*, Avitahl N, Sezaki N, Fujii N, Nakase K, Ninomiya Y, Harashima A, Minowada J, Tsuchiyama J, Imajoh K, Tsubota T, Fukuda S, Sezaki T, Kojima K, Hara M, Takimoto H, Yorimitsu S, Takahashi I, Miyata A, Taniguchi S, Tokunaga Y, Gondo H, Niho Y, Nakao S, Kyo T, Dohy H, Kamada N, Harada M. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Cancer Res. 1999; 59:3931-3934.
  () /, ()

11. Yasukawa M*, Ohminami H, Kojima K, Inokuchi K, Nishimura Y, Fujita S. Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia. Am J Hematol. 2000; 63:99-101.
  () /, ()

12. Yasukawa M*, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, Hirai H, Fujita S. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia derived dendritic cells to CD4(+) T lymphocytes. Blood. 2001; 98:1498-1505.
  () /, ()

13. Kojima K*, Kaneda K, Yasukawa M, Tanaka K, Inoue T Yamashita T, Dansako H, Sakugawa TS, Kozuka T, Hara M, Tanimoto M. Specificity of polymerase chain reaction-based clonality analysis of immunoglobulin heavy chain gene rearrangement for the detection of bone marrow infiltrate in B-cell lymphoma-associated haemophagocytic syndrome. Br J Haematol. 2002; 119:616-621.
  () /, ()

14. Kaneda K, Kojima K*, Takeuchi M, Takimoto H, Takaba S, Shinagawa K, Kobayashi H, Miyata A, Hara M, Tanimoto M. Can t(8;21) oligoblastic leukemia be called myelodysplastic syndromes? Eur J Haematol. 2002; 69:165-170.
  () /, ()

15. Fujii K, Aoyama M, Shinagawa K, Matsuo K*, Takenaka T, Ikeda K, Kojima K, Ishimaru I, Kiura K, Ueoka H, Niiya K, Tanimoto M, Harada M. Risk of Neutropenic Fever and Early Infectious Complications after Autologous Peripheral Blood Stem Cell Transplantation for Malignant Diseases. Int J Hematol. 2002; 76:186-191.
  () /, ()

16. Kozuka T*, Ikeda K, Teshima T, Kojima K, Matsuo K, Bessho A, Sunami K, Hiramatsu Y, Maeda Y, Noguchi T, Yamamoto K, Fujii N, Imai T, Takenaka K, Shinagawa K, Ishimaru F, Niiya K, Koide N, Tanimoto M, Harada M. Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. Transfusion. 2002; 42:1514-1522.
  () /, ()

17. Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S, Tanimoto M, Harada M, Yasukawa M*. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4(+) T lymphocytes. Leukemia. 2002; 16:2400-2407.
  () /, ()

18. Matsuo Y*, Drexler HG, Kojima K, Sugimoto A, Harashima A, Okochi A, Hara M, Orita K. Novel B-cell acute lymphoblastic leukemia sister cell lines BALM 19-23 and BALM-26 with interclonal proliferative and phenotypic heterogeneity from a patient with hypercalcemia. Hum Cell. 2002; 15:160-170.
  () /, ()

19. Matsuo Y*, Drexler HG, Kaneda K, Kojima K, Ohtsuki Y, Hara M, Yasukawa M, Tanimoto M, Orita K. Megakaryoblastic Leukemia cell line MOLM-16 derived from minimally differentiated acute leukemia with Myeloid/NK precursor phenotype. Leuk Res. 2003; 27:165-171.
  () /, ()

20. Kojima K*, Kaneda K, Yoshida C, Dansako H, Fujii N, Yano T, Shinagawa K, Yasukawa M, Fujita S, Tanimoto M. A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13). Br J Haematol 2003; 120:271-273.
  () /, ()

21. Yanai F, Ishii E, Kojima K, Hasegawa A, Azuma T, Hirose S, Suga N, Mitsudome A, Zaitsu M, Ishida Y, Shirakata Y, Sayama K, Hashimoto K, Yasukawa M*. Essential Roles of Perforin in Antigen-Specific Cytotoxicity Mediated by Human CD4(+) T Lymphocytes: Analysis Using the Combination of Hereditary Perforin-Deficient Effector Cells and Fas Deficient Target Cells. J Immunol. 2003; 170:2205-2213.
  () /, ()

22. Matsuo Y*, Drexler HG, Harashima A, Okochi A, Hasegawa A, Kojima K, Orita K. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing δ/λ type immunoglobulin. Leuk Res. 2004; 28:869-877.
  () /, ()

23. Kojima K*, Sakai I, Hasegawa A, Niiya H, Azuma T, Matsuo Y, Fujii N, Tanimoto M, Fujita S. FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23). Leukemia. 2004; 18:998-1005.
  () /, ()

24. Kozuka T*, Ikeda K, Teshima T, Yoshida C, Shinagawa K, Kojima K, Matsuo K, Bessho A, Sunami K, Hiramatsu Y, Maeda Y, Noguchi T, Yamamoto K, Fujii N, Imai T, Kusumoto KK, Masuda K, Takenaka K, Ishimaru F, Niiya K, Koide N, Tanimoto M, Harada M. Peripheral blood circulating immature cell counts predict CD34+ cell yields in G-CSF-induced PBPC mobilization in healthy donors. Transfusion. 2004; 44:526-532.
  () /, ()

25. Takeuchi K, Sakai I*, Narumi H, Yasukawa M, Kojima K, Minamoto Y, Fujisaki T, Tanimoto K, Hara M, Numata A, Gondo H, Takahashi M, Fujii N, Masuda K, Fujita S. Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha. Leuk Res. 2005; 29:173-178.
  () /, ()

26. Matsuo Y*, Drexler HG, Harashima A, Okochi A, Kojima K, Asakura S, Tanimoto M, Orita K. Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. Leuk Res. 2005; 29:701-710.
  () /, ()

27. Kojima K*, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, *Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005; 106:3150-3159.
  () /, ()

28. Kojima K, Konopleva M, McQueen T, O
  () /, ()

29. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M*. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. 2006; 5:2778-2786.
  () /, ()

30. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M*. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in AML cells. Cancer Res. 2007; 67:3210-3219.
  () /, ()

31. Kojima K *, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008; 22:1728-1736.
  () /, ()

32. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M*. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood. 2008; 112:2886-2895.
  () /, ()

33. Kojima K *, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009; 100:1128-1136.
  () /, ()

34. Hanaoka N, Nakakuma H*, Horikawa K, Nagakura S, Tsuzuki Y, Shimanuki M, Kojima K, Yonemura Y, Kawaguchi T. NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. Br J Haematol. 2009; 146:538-545.
  () /, ()

35. Kojima K *, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 via Mcl-1/Noxa axis. Leukemia. 2010; 24:33-43.
  () /, ()

36. Kojima K *, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010; 9:2545-2557.
  () /, ()

37. Jin L, Tabe Y*, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Letters. 2010; 299:161-170.
  () /, ()

38. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M*. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1a-mediated down-regulation of CXCL12. Blood. 2011; 118:4431-4439.
  () /, ()

39. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M*. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer. 2012; 118:1023-1031.
  () /, ()

40. Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, Miwa M, Okada S, Andreeff M, Saya H*. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene. 2012; 31:2849-2861.
  () /, ()

41. Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K†, Konopleva M†* († co-senior authors). Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012; 91:1861-1870.
  () /, ()

42. Kojima K*, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013; 121:4166-4174.
  () /, ()

43. Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M*. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med (Berl). 2013; 91:1383-1397.
  () /, ()

44. Lu H†, Kojima K†, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M* († equal contribution). Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia pre-clinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol. 2014; 98:485-492.
  () /, ()

45. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintas-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K*. Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014; 105:795-801.
  () /, ()

46. Tabe Y†, Kojima K†, Yamamoto S, Sekihara K, Matsushita H, Davis RE, Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M* († equal contribution). Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS One. 2015; 10:e0137210.
  () /, ()

47. Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Nogueras-Gonzalez GM, Huang X, Pierceall WE, Dettman EJ, Cardone MH, Shacham S, Konopleva M, Andreeff M*. Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs. PLoS One. 2015; 10:e0138377.
  () /, ()

48. Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M*. MDM2 Inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation. PLoS One. 2015; 10:e0139254.
  () /, ()

49. Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M*. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015; 6:37930-37947.
  () /, ()

50. Nishida Y, Maeda A, Chachad D, Ishizawa J, Yi Hua Q, Kornblau SM, Kimura S, Andreeff M, Kojima K*. Preclinical activity of the novel BMI-1 inhibitor PTC-209 in acute myeloid leukemia: implications for leukemia therapy. Cancer Sci. 2015; 106:1705-1713.
  () /, ()

51. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O
  () /, ()

52. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE*, Andreeff M*. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016; 9:ra17.
  () /, ()

53. Andreeff M*, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2016; 22:868-876.
  () /, ()

54. Kojima K*, Maeda A, Yoshimura M, Nishida Y, Kimura S. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma. Oncotarget. 2016; 7:69625-69637.
  () /, ()

55. Nishida Y, Maeda A, Kim MJ, Cao J, Kubota Y, Ishizawa Y, Al Rawi AN, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K*. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J. 2017; 7:e527.
  () /, ()

56. Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H*. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B cell acute leukemia. Blood. 2017; 129:1958-1968.
  () /, ()

57. Itamura H, Kubota Y*, Shindo T, Ando T, Kojima K, Kimura S. Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. Clin Lymphoma Myeloma Leuk. 2017; 17:370-374.
  () /, ()

58. Nishida Y, Kimura S*, Mizobe H, Yamamichi J, Kojima K, Kawaguchi A, Fujisawa M, Matsue K. Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. Sci Rep. 2017 Oct 10;7(1):12885.
  () /, ()

59. Maeda A, Nishida Y, Weetall M, Cao L, Branstrom A, Ishizawa J, Nii T, Schober WD, Abe Y, Matsue K, Yoshimura M, Kimura S, Kojima K*. Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. Oncotarget. 2018;9:28547-28560.
  () /, ()

60. Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M*. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res. 2018;78(10):2721-2731.
  () /, ()

61. Ureshino H*, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. Ann Hematol. 2019;98(2):465-471.
  () /, ()

62. Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S*. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 2019;24(4):445-453.
  () /, ()

63. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M*. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019;35(5):721-737.
  () /, ()

64. Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 2019 May 24. doi: 10.1038/s41375-019-0491-z. [Epub ahead of print] PubMed PMID: 31127149.
  () /, ()

総説1. Kojima K*, Hara M, Sawada T, Miyata A, Saito H, Matsuo Y, Yasukawa M, Fujita S, Harada M. Human T-lymphotropic virus type I provirus and T-cell prolymphocytic leukemia. Leuk Lymphoma. 2000; 38: 381-386.
  () /, ()

総説2. Kimura S*, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol. 2014; 19:3-9.
  () /, ()

総説3. Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 2015; 153:25-35.
  () /, ()

総説4. Kojima K*, Ishizawa J, Andreeff M. Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol. 2016; 44:791-798.
  () /, ()

■ 研究業績(著書)
1. Kojima K*, Vassilev LT. Targeting p53 tumor suppressor for AML therapy. In “Targeted Therapy of Acute Myeloid Leukemia”, ed. Michael A., pp.135-150, Springer, Berlin, 2015.()

2. Kojima K*, Andreeff M. TP53. In “Targeted Therapy in Translational Cancer Research”, ed. Tsimberidou AM, Kurzrock R, Anderson KC., pp. 353-359, John Wiley & Sons, Hoboken, NJ, 2015.()

■ 研究業績(口頭・ポスター)

■ 研究業績(特許)

■ 研究業績(その他の活動)
英文症例報告(1-10, *: corresponding author) 1. Kojima K*, Omoto E, Katayama Y, Uno M, Takada I, Kimura G, Kanehiro A, Tada S, Hayashi K, Kimura I, Sanada H, Harada M. Autoimmune Hemolytic Anemia in Allergic Granulomatous Angitis (Churg-Strauss Syndrome). Int J Hematol. 1996; 63:149-154. 2. Kojima K*, Sasaki T. Veno-Occlusive Disease in Hypereosinophilic Syndrome. Intern Med. 1995; 34:1194-1197. 3. Katayama Y*, Kojima K, Omoto E, Harada M. Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia. Int J Hematol. 1996; 65: 89-92. 4. Kojima K*, Miyake M, Nakagawa H, Yunoki Y, Ogurusu K, Saino S, Wani T, Kawaguchi Y. Multiple Gastric Carcinoids and Pituitary Adenoma in Type A gastritis. Intern Med. 1997; 36:787-789. 5. Kojima K*, Taniwaki M, Yoshino T, Katayama Y, Sunami K, Fukuda S, Omoto E, Harada M, Sezaki T. Trisomy 12 and t(14;18) in B-cell chronic lymphocytic leukemia. Int J Hematol. 1998; 67:199-203. 6. Kojima K*, Sawada T, Yasukawa M, Matsuo Y, Yakushijin Y, Narumi H, Azuma T, Takimoto H, Hara M. Deleted HTLV provirus in peripheral blood cells of a patient with T-cell prolymphocytic leukaemia. Br J Haematol. 1998; 100:567-570. 7. Kojima K*, Omoto E, Hara M, Sasaki K, Katayama Y, Nawa Y, Kimura Y, Azuma T, Takimoto H, Harada M. Myelodysplastic syndrome with translocation (8;21): a distinct myelodysplastic syndrome entity or M2-acute myeloid leukemia with extensive myeloid maturation? Ann Hematol. 1998; 76:279-282. 8. Kojima K*, Inoue Y, Katayama Y, Kataoka M, Sunami K, Fukuda S, Sezaki T, Omoto E, Harada M. Improvement with disodium cromoglycate of neutrophil phagocytosis and respiratory burst activity in a patient with hyperimmunoglobulin E syndrome. Allergy. 1998; 53:1101-1103. 9. Kojima K*, Yasukawa M, Hara M, Nawa Y, Kimura Y, Narumi H, Fujita S. Familial occurrence of chronic neutrophilic leukaemia. Br J Haematol. 1999; 105:428-430. 10. Kojima K*, Yasukawa M, Ishimaru F, Dansako H, Matsuo Y, Kimura Y, Nawa Y, Hara M, Harada M. Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous leukaemia in the blastic phase. Br J Haematol.1999; 106:720-722.()

英文症例報告(11-20, *: corresponding author) 11. Kojima K*, Mannami T, Yoshino T, Kawasaki H, Sasaki K, Maeda T, Furuya K, Harada M, Hara M. Histologic transformation of follicular lymphoma after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000; 26:581-583. 12. Miyata A*, Kojima K, Yoshino T, Fujii S, Shinagawa K, Ichimura K. Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia. Int J Hematol. 2001; 73:230-235. 13. Fujiwara T*, Kojima K, Ishimaru F, Harada M. Huge skin tumor diffuse large cell lymphoma associated with essential thrombocytosis. Intern Med. 2001; 40:843. 14. Sugimoto T, Imoto S*, Matsuo Y, Kojima K, Yasukawa M, Murayama T, Kohfuku J, Mizuno I, Yakushijin K, Sada A, Nishimura R, Koizumi T. T cell receptor γδ T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. Ann Hematol. 2001; 80:749-751. 15. Sakugawa M, Kojima K*, Kaneda K, Masuda K, Dansako H, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Harada M, Tanimoto M. Therapy related myelodysplastic syndrome/acute myeloid leukemia M2 and translocation (8;21). Ann Hematol. 2001; 80:763-766. 16. Ito W, Kojima K*, Fujiwara K, Nanba Y, Yoshino T, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Tanimoto M. Thymic Epithelial Hyperplasia with Nodular Sclerosis Hodgkin's Disease. Leuk Lymphoma. 2002;43:2229-2231. 17. Kojima K*, Fujii N, Takata S, Tezen T, Morikawa T, Kaneda K, Takenaka K, Itoshima I, Tanimoto M. Bilateral adrenal hemorrhage in essential thrombocythemia. Ann Hematol. 2002; 81:350-351. 18. Kojima K, Kurokawa SM*, Tanimoto K, Kojima Y, Hara M, Yoshino T, Harada M, Tanimoto M, Nishioka K, Kato T. Clonal expansion of limited T cell clonotypes in affected muscle from a patient with post-transplant polymyositis. Bone Marrow Transplant. 2002; 30:467-470. 19. Yoshida C, Kojima K*, Shinagawa K, Hashimoto D, Asakura S, Takata S, Tanimoto M. Fournier's gangrene after unrelated cord blood stem cell transplantation. Ann Hematol. 2002; 81:538-539. 20. Emori Y, Sakugawa M, Niiya K*, Kiguchi T, Kojima K, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Tanimoto M, Yamasaki R, Ohara N, Harada M. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis. 2002; 13:555-559.()

英文症例報告(21-30, *: corresponding author) 21. Fujii N*, Ikeda K, Takahashi N, Kojima K, Kobayashi Y, Ashiba A, Takenaka K, Fukuda S, Shinagawa K, Ishimaru F, Niiya K, Miura I, Tanimoto M, Harada M. Multilineage involvement in hypereosinophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8. Br J Haematol. 2002; 119:716-719. 22. Takata S, Kojima K*, Fujii N, Kaneda K, Yoshida C, Hashimoto D, Asakura S, Shinagawa K, Tanimoto M. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with t(6;8)(q15;q22). Cancer Genet Cytogenet. 2003; 140:167-169. (Renamed as Cancer Genetics) 23. Kojima K*, Fujii N, Omoto E, Nose S, Yoneyama M, Sugii Y, Hiramatsu H, Chikatsune M, Sato M, Takata S, Itoshima T, Tanimoto M. Cyclic thrombocytopenia and polycythemia vera. Ann Hematol. 2003; 82:61-63. 24. Kozuka T, Kojima K*, Kaneda K, Takenaka K, Manabe Y, Hirata Y, Okuma S, Toki H, Tanimoto M. Autoimmune neutropenia associated with multiple sclerosis. Intern Med. 2003; 42:102-104. 25. Kojima K*, Imaoka M, Noguchi T, Narumi H, Uchida N, Sakai I, Yasukawa M, Fujita S. Hypocellular acute promyelocytic leukemia with a tetraploid clone characterized by two 15;17 translocations. Cancer Genet Cytogenet. 2003; 145:169-171. (Renamed as Cancer Genetics) 26. Narumi H, Kojima K*, Matsuo Y, Shikata H, Sekiya K, Niiya T, Bando S, Niiya H, Azuma T, Yakushijin Y, Sakai I, Yasukawa M, Fujita S. T-cell large granular lymphocyte leukemia occurring after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2004;33:99-101. 27. Azuma T*, Narumi H, Kojima K, Nawa Y, Hara M. Hyponatremia during administration of tacrolimus in an allogeneic bone marrow transplant recipient. Int J Hematol. 2003; 78:268-269. 28. Fujimoto TT*, Kishimoto M, Ide K, Mizushima M, Mita M, Sezaki N, Kojima K, Shinagawa K, Niiya K, Tanimoto M, Fujimura K. Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. Int J Hematol. 2005; 81:77-80. 29. Yakushijin Y*, Shikata H, Kito K, Ohshima K, Kojima K, Hato T, Hasegawa H, Yasukawa M. Follicular dendritic cell tumor as an unknown primary tumor. Int J Clin Oncol. 2007; 12:56-58. 30. Ravella PM, Liu D, Kojima K, Weisberger J, Miura O, Kuyama J, Au W, Seiter K*. Acute promyelocytic leukemia with tetraploid karyotype. First report in the Western hemisphere and update of previous reports. Leuk Res. 2011; 35:e93-e95.()

英文症例報告(31-40, *: corresponding author) 31. Kitamura H*, Ando T, Kojima K, Komiya K, Sueoka-Aragane N, Kimura S. Diffuse bone marrow uptake of fluorodeoxyglucose in a patient with aleukaemic acute lymphoblastic leukaemia. Br J Haematol. 2014; 166:2. 32. Kamachi K, Kojima K*, Nishijima A, Takeshita M, Ando T, Kimura S. Small lymphocytic lymphoma presenting as bulky renal incidentaloma. Int J Hematol. 2014; 100:107-108. 33. Kamachi K, Fukushima N*, Ando T, Sato K, Ohshima K, Yokoo M, Shindo T, Kubota Y, Kojima K, Kimura S. Coexistence of ALK-anaplastic large cell lymphoma and CD4+ T cell large granular lymphocytic leukemia. Ann Hematol. 2015; 94:539-540. 34. Yoshimura M, Kojima K*, Tomimasu R, Fukushima N, Hayashi S, Sueoka E, Kimura S. ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. Int J Hematol. 2014; 100:611-614. 35. Ando T, Kojima K*, Isoda H, Eguchi Y, Honda T, Ishigami M, Kimura S. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015; 102:379-382. 36. Ureshino H*, Ando T, Kojima K, Itamura H, Jinnai S, Doi K, Ohshima K, Kurogi K, Miyahara M, Kimura S. Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma. Intern Med. 2015; 54:3205-3208. 37. Ureshino H, Nishioka A, Kojima K*, Suzuki M, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma. Intern Med. 2016; 55:2061-2064. 38. Ureshino H, Nishioka A, Kojima K*, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Intern Med. 2016; 55:2703-2706. 39. Kusaba K, Kojima K*, Naito S, Taba M, Kai K, Ureshino H, Nishida Y, Kimura S. Paraneoplastic Sarcoidosis in Multiple Myeloma. Intern Med. 2017; 56:2049-2051. 40. Ureshino H*, Kizuka H, Kusaba K, Sano H, Nishioka A, Shindo T, Kubota, Y, Ando T, Kojima K, Kimura S. 5q− syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). Int J Hematol. 2017; 105:692-696.()

英文症例報告(41-48, *: corresponding author) 41. Ureshino H*, Ando T, Kizuka H, Kusaba K, Sano H, Nishioka A, Itamura H, Shindo T, Kubota Y, Kojima K, Kimura S. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018;36:324-327. 42. Kitamura H, Kubota Y*, Yamaguchi K, Kamachi K, Nishioka A, Yokoo M, Shindo T, Ando T, Kojima K, Kimura S. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. Intern Med. 15;57:855-860. 43. Nishioka A, Ureshino H*, Ando T, Kizuka H, Kusaba K, Sano H, Itamura H, Kubota Y, Kojima K, Ohshima K, Kimura S. Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma. Int J Hematol. 2018;107:703-708. 44. Ando T, Kojima K*, Sano H, Kidoguchi K, Kusaba K, Yoshimura M, Yokoo M, Kubota Y, Nakamura H, Takase Y, Aishima S, Kimura S. Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. Leuk Lymphoma. 2018 Oct;59(10):2474-2477. doi: 10.1080/10428194.2018.1427859. Epub 2018 Jan 31. PubMed PMID: 29382244. 45. Kidoguchi K, Yoshimura M, Kojima K*, Ureshino H, Egashira R, Yokoo M, Kai K, Egashira Y, Ohshima K, Ando T, Kimura S. Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. Ann Hematol. 2019;98:1305-1307. 46. Yokoo M, Kojima K*, Sano H, Kai K, Arakawa F, Ohshima K, Matsunaga T, Kimura S. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. Ann Hematol. 2018 Nov 8. doi: 10.1007/s00277-018-3543-y. [Epub ahead of print] PubMed PMID: 30406822. 47. Kidoguchi K, Kojima K*, Seki R, Nagafuji K, Ohshima K, Kimura S. Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases? Int J Hematol. 2019 Mar;109(3):247-248. doi: 10.1007/s12185-018-02585-8. Epub 2019 Jan 3. PubMed PMID: 30604315. 48. Kamachi K, Kubota Y*, Nagaie T, Yamaguchi Y, Ogusu S, Kidoguchi K, Kusaba K, Kizuka-Sano H, Nishioka A, Yoshimura M, Yokoo M, Ando T, Kai K, Kojima K, Ohshima K, Sueoka E, Kimura S. Primary chest wall MYC/BCL6 double-hit lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) translocations. Intern Med, in press.()


前ページへ戻る